Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

FBLG - FibroBiologics, Inc. Latest News | Finranks

Home

FBLG

F

FibroBiologics, Inc. (FBLG)

NCM – Real Time Price. Currency in USD

0.20

-0.02 (-10.64%)

At close: Mar 27, 2026, 4:00 PM EDT

0.20

+0.00 (1.17%)

After-hours: Mar 27, 2026, 7:49 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's issued and outstanding common stock. The reverse stock split is expected to become effective at 12:01 a.m.

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using proprietary fibroblast spheroid technology, today announced the expansion of its wound care platform into the treatment of patients with acute and chronic burn injuries.

$FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers$

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs). The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics' investigational topically administered allogeneic fibroblast spheroid-based therapy, CYWC628, for the treatment of refractory DFUs.

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled “Fibroblast Cell Therapy for Treatment of Osteoporosis.”